Even though immune checkpoint blockade can cause organ-specific immune-related adverse events, such as hepatitis and colitis, as well as systemic inflammation [43]; further studies are needed to determine whether blockade of the PD1/PDL1 pathway can be used to improve therapies against infectious diseases. This evidence concerns the gene CD274 and colitis.